Doreen Kunze

Summary

Country: Germany

Publications

  1. request reprint
    Kunze D, Fuessel S, Meye A, Wirth M, Schmidt U. Functional analyses of C13orf19/P38IP in prostate cell lines. Oncol Rep. 2006;15:1599-604 pubmed
    ..No interaction between C13orf19 and p38MAPK was identified. Therefore, the gene should forthwith be named C13orf19 or Fam48A and not P38IP. ..
  2. request reprint
    Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol. 2008;32:1049-56 pubmed
    ..In vivo studies with 9 consecutive intraperitoneal injections with 20 mg/kg AS-ODNs or 4.6 mg/kg siRNAs revealed the biocompatibility of both antisense inhibitor types and showed anti-tumoural activity of the AS-ODNs used. ..
  3. Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth M, Fuessel S. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 2012;41:1271-7 pubmed publisher
    ..5-fold enhancement in apoptosis rate and reduced cellular viability by 40%. Therefore, simultaneous knockdown of antiapoptotic BCL2, Bcl?xL, XIAP and survivin may represent a promising treatment option for bladder cancer. ..

Locale

Detail Information

Publications3

  1. request reprint
    Kunze D, Fuessel S, Meye A, Wirth M, Schmidt U. Functional analyses of C13orf19/P38IP in prostate cell lines. Oncol Rep. 2006;15:1599-604 pubmed
    ..No interaction between C13orf19 and p38MAPK was identified. Therefore, the gene should forthwith be named C13orf19 or Fam48A and not P38IP. ..
  2. request reprint
    Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol. 2008;32:1049-56 pubmed
    ..In vivo studies with 9 consecutive intraperitoneal injections with 20 mg/kg AS-ODNs or 4.6 mg/kg siRNAs revealed the biocompatibility of both antisense inhibitor types and showed anti-tumoural activity of the AS-ODNs used. ..
  3. Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth M, Fuessel S. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 2012;41:1271-7 pubmed publisher
    ..5-fold enhancement in apoptosis rate and reduced cellular viability by 40%. Therefore, simultaneous knockdown of antiapoptotic BCL2, Bcl?xL, XIAP and survivin may represent a promising treatment option for bladder cancer. ..